By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.

OK

By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.

Celltrion

Celltrion’s Stelara biosimilar secures UK approval Korea Biomedical Review02:09Stelara UK Health

Celltrion's Stelara biosimilar receives approval in UK The Korea Herald06:06Stelara UK Health

Celltrion's SteQeyma approved to treat inflammatory disease in Britain Korea JoongAng Daily10:14Cancer Treatment Biotechnology

Celltrion Pharm's 3 biosimilars 24-36% cheaper than originals in Korea Korea Biomedical Review04:05

EC approves Celltrion’s Stelara biosimilar SteQeyma for inflammatory diseases PMLiVE12:23European Commission

Celltrion partners with Cigna Healthcare to expand access to Zymfentra Korea Biomedical Review07:53Cigna Healthcare ZYMFENTRA Inflammatory Bowel Disease

Biosimilar updates: Celltrion, Costco partnership; Amgen sues Samsung Bioepis; denosumab results American Journal of Managed Care15:31Samsung Bioepis

Eye on pharma: Celltrion, Costco partnership; Amgen sues Samsung Bioepis; denosumab results Center for Biosimilars12:23Samsung Bioepis

Celltrion eyes new production plant, aims for W5tr in sales The Korea Herald07:20

Celltrion's autoimmune disease biosimilars achieve solid growth in Italy Korea Biomedical Review02:39Italy Southern Europe

Celltrion’s SteQeyma receives EC approval for chronic inflammatory diseases Pharmaceutical Technology13:09Steqeyma European Commission

Celltrion scores approval for Stelara biosimilar in Europe Korea Biomedical Review06:03Steqeyma European Commission

Latest News

Earlier today

Celltrion eyes new production plant, aims for W5tr in sales The Korea Herald07:20

Celltrion aims to achieve $3.7 bil. in sales in 2025, says Chairman Seo Korea Biomedical Review03:14

In the last 7 days

Celltrion's SteQeyma approved to treat inflammatory disease in Britain Korea JoongAng Daily10:14 4-Sept-24

Celltrion's Stelara biosimilar receives approval in UK The Korea Herald06:06 4-Sept-24

Celltrion’s Stelara biosimilar secures UK approval Korea Biomedical Review02:09 4-Sept-24

Celltrion Pharm's 3 biosimilars 24-36% cheaper than originals in Korea Korea Biomedical Review04:05 2-Sept-24

In the last month

EC approves Celltrion’s Stelara biosimilar SteQeyma for inflammatory diseases PMLiVE12:23 29-Aug-24

Celltrion partners with Cigna Healthcare to expand access to Zymfentra Korea Biomedical Review07:53 29-Aug-24

Celltrion USA partners with Express Scripts and Cigna Healthcare to expand access to Zymfentra® (infliximab-dyyb), the… AsiaOne02:10 29-Aug-24

Celltrion’s SteQeyma receives EC approval for chronic inflammatory diseases Pharmaceutical Technology13:09 26-Aug-24

Celltrion gets European approval for Stelara biosimilar The Korea Herald06:23 26-Aug-24

Celltrion scores approval for Stelara biosimilar in Europe Korea Biomedical Review06:03 26-Aug-24

European Commission approves Celltrion’s SteQeyma® (CT-P43), a biosimilar to Stelara®… Business Wire (Press Release)00:00 26-Aug-24

Biosimilar Updates: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results American Journal of Managed Care15:31 25-Aug-24

Celltrion's autoimmune disease biosimilars achieve solid growth in Italy Korea Biomedical Review02:39 23-Aug-24

Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results Center for Biosimilars12:23 21-Aug-24

Celltrion eyes top 5 drug maker by 2030 The Korea Herald06:14 19-Aug-24

FDA approves Celltrion's phase 3 trial of Zymfentra for rheumatoid arthritis Korea Biomedical Review03:50 19-Aug-24

Celltrion scraps merger plan after investor backlash The Korea Herald08:53 16-Aug-24

Celltrion, Celltrion Pharm cancel merger due to shareholder pushback Korea JoongAng Daily03:10 16-Aug-24

Celltrion decides not to merge with chemical drug-producing unit Yonhap News Agency03:07 16-Aug-24

Celltrion Group decides against merger between Celltrion and Celltrion Pharm Korea Biomedical Review02:55 16-Aug-24

Celltrion receives go-ahead for P3 study for Cosentyx biosimilar in US Korea Biomedical Review08:50 14-Aug-24

Celltrion to finalize merger decision with Celltrion Pharm on Friday this week Korea Biomedical Review09:11 13-Aug-24

Celltrion begins Yuflyma sale at Costco in US Korea Biomedical Review07:00 13-Aug-24

Celltrion USA announces incorporation of adalimumab-aaty, a Humira® biosimilar, to the Costco… PR Newswire (Press Release)00:46 13-Aug-24

Spotlight On: Biosimilar Litigations - August 2024 JD Supra20:40 12-Aug-24

Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) / Riabni™ (rituximab-arrx)… JD Supra19:09 12-Aug-24

US Biosimilar Market Research 2024-2028 Featuring Leading Players - Pfizer, Novartis, Amgen, Samsung Biologics,… GlobeNewswire (Press Release)10:36 12-Aug-24

Celltrion gets FDA approval for phase 3 trial of Keytruda biosimilar The Korea Herald07:12 12-Aug-24

Celltrion's CT-P51 biosimilar to Keytruda receives FDA nod for phase 3 study Korea Biomedical Review03:56 12-Aug-24

view more headlines

9 Sept 07:20

About our Celltrion news

Latest news on Celltrion, a biopharmaceutical company headquartered in Incheon, South Korea.

Publication filters

Notifications

Unsubscribe from Breaking News

Sorry, no headlines or news topics were found. Please try different keywords.